Background of the Withdrawal of Estrogen Receptor Modulator Authorization in Europe

Eli Lilly and Company (LLY) has voluntarily withdrawn the Marketing Authorisation for Optruma (active ingredient: raloxifene hydrochloride), a treatment for postmenopausal osteoporosis, registered with the European Medicines Agency (EMA). Optruma is a selective estrogen receptor modulator (SERM) that was approved through the EU centralized procedure in August 1998. This action was not a forced removal due to regulatory safety warnings or efficacy defects, but rather a business decision made by the rights holder, Eli Lilly Nederland B.V. This can be interpreted as a typical portfolio rationalization strategy, where a global pharmaceutical company streamlines redundant licenses that have persisted long after patent expiration to reduce regulatory maintenance costs.

Addressing Cannibalization with Evista, Which Shares the Same Ingredients

Optruma was launched as a "twin brand" sharing the same active ingredient and dosage (60 mg tablets) as Lilly's flagship osteoporosis treatment, Evista. The dual brand structure, originally intended to target multiple distribution channels in Europe, gradually became an inefficient asset following the expiration of raloxifene's exclusivity and the entry of generics. Specifically, the structure involved continuous costs, such as annual renewal fees to European regulatory authorities amounting to tens of millions of won and the maintenance of pharmacovigilance obligations. Through this withdrawal, Lilly is streamlining its low-profit residual brands to concentrate resources on its core brand, Evista, and its subsequent metabolic disease pipeline.

Clinical Efficacy Proven by the Large-Scale Phase 3 MORE Study

The active ingredient of Optruma, raloxifene, is a drug with proven efficacy through the MORE (Multiple Outcomes of Raloxifene Evaluation) study, a landmark Phase 3 clinical trial involving 7,705 postmenopausal osteoporosis patients. In this study, the 60mg raloxifene group demonstrated a significant reduction in the risk of new vertebral fractures by 30% in patients with baseline fractures and 55% in patients without fractures compared to the placebo group. However, it failed to achieve statistical significance in preventing non-vertebral and hip fractures and showed a side effect profile including an increased risk of venous thromboembolism. These limitations in clinical efficacy acted as a decisive factor restricting its expansion as a first-line treatment compared to the bisphosphonate class.

Generational Shift in the $15 Billion Osteoporosis Market and Patient Impact

The global osteoporosis treatment market, estimated at approximately $15 billion (USD), is undergoing a definitive generational shift in mechanisms. Bisphosphonates, such as alendronate, have firmly established themselves as the standard treatment for low-cost generic therapy, while the market for severe patients is dominated by Amgen's RANKL inhibitor Prolia (denosumab) and Lilly's parathyroid hormone derivative Forteo (teriparatide). Since multiple raloxifene generics are already available in the European market at low prices, there is virtually no risk of a medication gap or decreased treatment access for patients due to the withdrawal of Optruma. Consequently, this case clearly demonstrates the end of the lifecycle for first-generation targeted therapies and the process of drug rationalization within a mature market.